v3.25.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Information

The following table is representative of revenue and significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment (in thousands):

 

   2025   2024   2025   2024 
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2025   2024   2025   2024 
Revenues  $422   $-   $619   $- 
Program expenses (1)                    
Clinical trial studies    539    604    1,209    1,320 
Manufacturing development, RenovoCath    383    188    720    225 
Other research and development expenses   78    13    204    16 
Non-program expenses (2)   998    1,105    2,104    1,992 
Personnel compensation and related expenses, including share-based compensation   1,102    1,124    2,170    1,957 
Other segment items (3)   217    (645)   (473)   (2,045)
Net loss  $(2,895)  $(2,389)  $(5,315)  $(3,465)

 

  (1) Includes external research expenses, clinical studies, manufacturing development and non-recurring engineering costs, professional and consulting, regulatory, and trade shows.
  (2) Includes selling, general and administrative expenses for professional and consulting expenses, audit fees, board fees, legal expenses, insurance expenses, travel, and other office expenses.
  (3) Includes interest income and interest expense and gain recognized on the fair value of common stock warrant liability.